Updates are available Correction dated 2024-03-21
Click to view Correction: https://doi.org/10.1038/s41590-024-01799-9
-
Authors
Gao, Yulong
Souza-Fonseca-Guimaraes, Fernando
Bald, Tobias
Ng, Susanna S
Young, Arabella
Ngiow, Shin Foong
Rautela, Jai
Straube, Jasmin
Waddell, Nic
Blake, Stephen J
Yan, Juming
Bartholin, Laurent
Lee, Jason S http://orcid.org/0000-0003-0879-934X
Vivier, Eric http://orcid.org/0000-0001-7022-8287
Takeda, Kazuyoshi
Messaoudene, Meriem
Zitvogel, Laurence
Teng, Michele W L
Belz, Gabrielle T http://orcid.org/0000-0002-9660-9587
Engwerda, Christian R
Huntington, Nicholas D http://orcid.org/0000-0002-5267-7211
Nakamura, Kyohei
Hölzel, Michael
Smyth, Mark J http://orcid.org/0000-0001-7098-7240
- License Information
-
More Information
Article History
Received: 17 April 2017
Accepted: 23 June 2017
First Online: 31 July 2017
Change Date: 21 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-024-01799-9
Competing interests
: M.J.S. has research agreements with Bristol-Myers Squibb, Corvus Pharmaceuticals and Aduro Biotech; E.V. is a cofounder and shareholder in Innate Pharma; and N.D.H. and J.R. are cofounders and shareholders in oNKo-Innate.
